Another key part of our philosophy is giving back
FDA-approved GLP-1 receptor agonists undergo extensive manufacturing controls, stability testing, and quality assurance
Current research gaps include long-term safety data, optimal dosing protocols for different populations, and comprehensive efficacy studies in diverse patient groups
For type 2 diabetes, treatment should continue only if there is at least 11 mmol/mol (1.0%) reduction in HbA1c and weight loss of at least 3%
However, the journey from understanding the basic mechanisms to the application of these insights in clinical settings involves overcoming several challenges, including optimizing drug efficacy, minimizing side effects, and ensuring long-term safety and tolerability